---
title: "Guggenheim maintains Buy rating on Elevance Health, $485 price target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302762260.md"
description: "Guggenheim maintains a Buy rating on Elevance Health with a $485 price target, implying an 11.7% upside from the Oct 21 close of $434.13. The firm cites strong earnings growth potential driven by Medicaid margin improvements, favorable ACA claims experience, and Carelon services expansion. Additionally, Elevance's robust market position as the largest Blue Cross Blue Shield provider, bolstered by acquisitions like Amerigroup and MMM, supports future growth opportunities."
datetime: "2026-10-22T18:06:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302762260.md)
  - [en](https://longbridge.com/en/news/302762260.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302762260.md)
generator: "portal-rs"
---

# Guggenheim maintains Buy rating on Elevance Health, $485 price target

Guggenheim maintained their Buy rating on Elevance Health's stock with a price target of $485.00.

The price target implies an upside of 11.7% from the Oct 21 close of $434.13.

**Key takeaways from the analyst note**

**Strong Earnings Growth Potential**: Elevance Health is expected to achieve over 12% EPS growth due to a combination of Medicaid margin improvements, favorable claims experience in the ACA market, and ongoing growth in its Carelon services, which positions the company for sustained financial performance.

**Robust Market Position and Strategic Acquisitions**: As the largest provider of Blue Cross Blue Shield coverage and through strategic acquisitions like Amerigroup and MMM, Elevance has enhanced its presence in government-sponsored programs, solidifying its market position and driving future growth opportunities.

Explore more price target data and ratings for Elevance Health on the .

**Disclaimer**

Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [ELV.US](https://longbridge.com/en/quote/ELV.US.md)

## Related News & Research

- [Elevance Health, Inc. $ELV Shares Acquired by Robeco Institutional Asset Management B.V.](https://longbridge.com/en/news/302684364.md)
- [Is Elevance Health (ELV) Still Undervalued Following Strong Earnings And Higher 2026 Guidance?](https://longbridge.com/en/news/302983253.md)
- [Elevance Health, Inc. $ELV Stock Position Cut by Vontobel Holding Ltd.](https://longbridge.com/en/news/302257360.md)
- [Elevance Health Reports Third Quarter 2026 Results; Raises Full-Year Guidance | ELV Stock News](https://longbridge.com/en/news/302545860.md)
- [ELV: Q3 outperformance lifts 2026 guidance; long-term adjusted EPS growth target remains 12%](https://longbridge.com/en/news/302542475.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**